Edition:
United States

ACADIA Pharmaceuticals Inc (ACAD.OQ)

ACAD.OQ on NASDAQ Stock Exchange Global Select Market

28.25USD
22 Nov 2017
Change (% chg)

$0.36 (+1.29%)
Prev Close
$27.89
Open
$27.83
Day's High
$28.27
Day's Low
$27.68
Volume
202,236
Avg. Vol
455,356
52-wk High
$41.20
52-wk Low
$24.32

Chart for

About

ACADIA Pharmaceuticals Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of medicines for central nervous system (CNS) disorders. Its lead drug candidate, NUPLAZID (pimavanserin), is used for the treatment of hallucinations and delusions associated with Parkinson's disease... (more)

Overall

Beta: 3.93
Market Cap(Mil.): $3,457.81
Shares Outstanding(Mil.): 122.40
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 189.94 15.47
EPS (TTM): -- -- --
ROI: -- -10.73 11.81
ROE: -- -36.69 15.76

BRIEF-Acadia Pharmaceuticals posts Q3 loss of $0.53 per share

* Acadia Pharmaceuticals reports third quarter 2017 financial results

Nov 07 2017

BRIEF-Acadia Pharmaceuticals initiates phase III study of Pimavanserin

* Acadia Pharmaceuticals initiates phase III study of Pimavanserin in dementia-related psychosis

Oct 04 2017

Big-name U.S. hedge funds shed healthcare stocks during the rally in second-quarter

NEW YORK Several big-name hedge fund investors trimmed their stakes in healthcare companies in the second quarter as the sector led the broad U.S. stock market higher, rallying amid a Republican effort to repeal and replace President Obama's signature healthcare law.

Aug 14 2017

BRIEF-Acadia pharmaceuticals Q2 loss per share $0.55

* Acadia pharmaceuticals reports second quarter 2017 financial results

Aug 08 2017

BRIEF-ACADIA Pharmaceuticals Q2 loss per share $0.55

* ACADIA Pharmaceuticals Inc - ‍expects that full-year NUPLAZID net sales for 2017 will be between $105 million and $115 million​

Aug 08 2017

Competitors

  Price Chg
Pfizer Inc. (PFE.N) $35.43 -0.11
Eli Lilly and Co (LLY.N) $83.68 +0.17
Eisai Co., Ltd (4523.T) ¥6,295 --

Earnings vs. Estimates